CytomX Therapeutics (CTMX) Return on Sales (2014 - 2026)

CytomX Therapeutics' Return on Sales history runs 13 years deep, the most recent figure standing at 0.02% for Q1 2026.

• Quarterly Return on Sales fell 2.0% year-over-year to 0.02% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.02% (down 2.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
• Return on Sales was 0.02% for Q1 2026 at CytomX Therapeutics, up from 0.34% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q4 2024 and bottomed at 0.34% in Q4 2025.
• A 5-year average of 0.03% and a median of 0.0% in 2023 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2022 — Return on Sales advanced 3 bps — and 2025, when it slumped 35 bps.
• CytomX Therapeutics' Return on Sales stood at 0.0% in 2022, then jumped by 107 bps to 0.0% in 2023, then jumped by 1475 bps to 0.0% in 2024, then slumped by 7002 bps to 0.34% in 2025, then surged by 95 bps to 0.02% in 2026.
• Business Quant data shows CTMX's Return on Sales at 0.02% in Q1 2026, 0.34% in Q4 2025, and 0.02% in Q3 2025.